The introduction of biological tumor necrosis factor inhibitors has improved the treatment of rheumatoid arthritis (RA) but at a substantial cost. These drugs have been shown to lead to superior radiological outcomes compared with a combination of conventional disease-modifying antirheumatic drugs over 2 years.
To investigate whether radiological superiority translates into better work loss outcomes.
Multicenter, 2-arm, parallel, randomized, active-controlled, open-label trial. Patients with early RA (symptom duration
Notes
Comment In: JAMA Intern Med. 2013 Aug 12;173(15):1414-523817526
Comment In: Dtsch Med Wochenschr. 2013 Oct;138(44):223624150698